PFIZERPharmaceuticals
Pfizer Ltd — Cash Flow Statement
₹4720.50
-0.37%
Pfizer Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 631.60 Cr | 237.91 Cr | 290.70 Cr | 651.77 Cr | — |
| Capital Expenditure | -28.15 Cr | -18.93 Cr | -64.98 Cr | -15.31 Cr | — |
| End Cash Position | 495.07 Cr | 112.00 Cr | 36.60 Cr | 62.76 Cr | — |
| Beginning Cash Position | 112.00 Cr | 36.60 Cr | 62.76 Cr | 151.21 Cr | — |
| Changes In Cash | 383.07 Cr | 75.40 Cr | -26.16 Cr | -88.45 Cr | — |
| Financing Cash Flow | -205.34 Cr | -235.14 Cr | -345.79 Cr | -180.51 Cr | — |
| Interest Paid Cff | -7.78 Cr | -10.66 Cr | -13.38 Cr | -10.88 Cr | — |
| Cash Dividends Paid | -160.25 Cr | -183.43 Cr | -297.21 Cr | -159.74 Cr | — |
| Investing Cash Flow | -71.34 Cr | 53.70 Cr | -36.05 Cr | -575.02 Cr | — |
| Net Other Investing Changes | 19.84 Cr | 0.15 Cr | 5.41 Cr | 6.96 Cr | — |
| Interest Received Cfi | 139.36 Cr | 128.83 Cr | 71.11 Cr | 43.77 Cr | — |
| Net Investment Purchase And Sale | -354.27 Cr | -109.25 Cr | -229.29 Cr | -612.50 Cr | — |
| Net PPE Purchase And Sale | 123.73 Cr | 33.97 Cr | -63.76 Cr | -13.25 Cr | — |
| Sale Of PPE | 151.88 Cr | 52.90 Cr | 1.22 Cr | 2.06 Cr | — |
| Purchase Of PPE | -28.15 Cr | -18.93 Cr | -64.98 Cr | -15.31 Cr | — |
| Operating Cash Flow | 659.75 Cr | 256.84 Cr | 355.68 Cr | 667.08 Cr | — |
| Taxes Refund Paid | -156.22 Cr | -153.82 Cr | -302.58 Cr | -225.92 Cr | — |
| Change In Working Capital | 56.79 Cr | -246.09 Cr | -34.49 Cr | 43.94 Cr | — |
| Change In Other Current Liabilities | 21.94 Cr | -55.24 Cr | -29.40 Cr | 7.07 Cr | — |
| Change In Other Current Assets | 67.61 Cr | -37.40 Cr | 73.38 Cr | 73.15 Cr | — |
| Change In Payable | -15.31 Cr | -50.20 Cr | -38.11 Cr | -11.19 Cr | — |
| Change In Inventory | -42.22 Cr | -16.00 Cr | 21.85 Cr | -13.86 Cr | — |
| Change In Receivables | -6.82 Cr | -36.51 Cr | -10.20 Cr | -18.35 Cr | — |
| Other Non Cash Items | -161.96 Cr | -162.59 Cr | -82.52 Cr | -46.07 Cr | — |
| Stock Based Compensation | 13.66 Cr | 14.45 Cr | 12.70 Cr | 11.77 Cr | — |
| Provisionand Write Offof Assets | 1.67 Cr | 1.76 Cr | 2.52 Cr | 5.70 Cr | — |
| Deferred Tax | 0.00 | -7.95 Cr | 86.71 Cr | 0.00 | — |
| Depreciation And Amortization | 60.79 Cr | 62.28 Cr | 105.51 Cr | 115.00 Cr | — |
| Amortization Cash Flow | 9.96 Cr | 9.96 Cr | 50.32 Cr | 50.32 Cr | — |
| Depreciation | 50.83 Cr | 52.32 Cr | 55.19 Cr | 115.00 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.21 Cr | -0.32 Cr | -0.09 Cr | -8.65 Cr | — |
| Gain Loss On Sale Of PPE | -171.28 Cr | 3.05 Cr | -0.05 Cr | -1.58 Cr | — |
| Net Income From Continuing Operations | 1.02K Cr | 746.07 Cr | 824.01 Cr | 772.89 Cr | — |
| Net Business Purchase And Sale | — | 0.00 | 180.48 Cr | 0.00 | — |
| Sale Of Business | — | 0.00 | 180.48 Cr | 0.00 | — |
| Gain Loss On Sale Of Business | — | 0.00 | -256.04 Cr | 0.00 | -24.36 Cr |
| Purchase Of Investment | — | — | — | -612.50 Cr | -501.99 Cr |
| Net Intangibles Purchase And Sale | — | — | — | — | 0.00 |
| Sale Of Intangibles | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Pfizer Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.